Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine
Qualitative test to monitor medication compliance and to detect undisclosed drug/substance use in support of pain management, substance use disorders treatment, and other pharmacotherapies involving controlled substances. Expert result interpretation is provided by a faculty clinical toxicologist.
Submission of a medication history is required to optimize reporting; refer to ARUP's Medication Submission Guidelines for details. If a medication history is not available or interpretation is not desired, refer to Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2007479).
This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
New York DOH Approval Status
Information on the patient's current medications must be submitted with the order. Include trade name, generic name, dosing frequency, and date of last dose, if known. Alternatively, please indicate if no prescription medication or drugs are being taken.
Transfer 4 mL each into two (2) ARUP standard transport tubes of urine with no additives or preservatives. (Min: 2 mL each)
Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week (Clonazepam may be unstable at ambient condition beyond three days); Refrigerated: 1 month; Frozen: 1 month
Quantitative Tandem Mass Spectrometry/Qualitative Enzyme Multiplied Immunoassay Technique (EMIT)/Quantitative Spectrophotometry
|Drugs covered and range of cutoff concentrations.
Note: Some drugs are identified based on the presence of unique drug metabolites not listed below.
||Range of Cutoff Concentrations
alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, zolpidem
|20 - 60 ng/mL|
|Cannabinoids (11-nor-9-carboxy-THC)||50 ng/mL|
|Ethyl Glucuronide||500 ng/mL|
buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone, oxycodone, oxymorphone, tapentadol, tramadol
|Phencyclidine (PCP)||25 ng/mL|
amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine
Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
Laboratory Developed Test (LDT)
Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.
80326; 80347; 80364; 80355; 80307 (Alt code: G0481)
|Component Test Code*||Component Chart Name||LOINC|
|2007654||Meperidine metabolite, U||58388-0|
|2007658||Methadone Screen, U||3773-9|
|2007660||Tramadol Screen, U||43219-5|
|2007670||Cocaine Screen, U||3393-6|
|2007684||Barbiturates Screen, U||3377-9|
|2007687||Ethyl Glucuronide Screen, U||55349-5|
|2007688||THC (Cannabinoids) Screen, U||3435-5|
|2007689||Phencyclidine Screen, U||3936-2|
|2007690||Carisoprodol Screen, U||21142-5|
|2007691||Targeted Drug Profile Comment||8251-1|
|2009289||EER Targeted Drug Profile, U||11526-1|
|2009291||Targeted Drug Profile Interpretation||48767-8|
|3003500||Zolpidem Metabolite, U||94103-9|
- abstinence verification
- addiction management
- Comprehensive hybrid
- high res
- medication adherence
- medication compliance
- Pain management, (drug screen, targeted, urine)
- prenatal drug screen
- substance use disorder